September 09, 2011 -- On August 23 to 25 Amoy Diagnostics and AstraZeneca co-hosted the 8th in a series of workshops about the use of the ADx-EGFR Mutation Detection Assay. The training sessions were attended by physicians and pathologists involved in diagnosing and treating lung cancer patients.
The EGFR mutation detection assay is now widely used in mainland China to identify patients most likely to respond to Iressa, AstraZeneca’s anti-EGFR signaling drug. The meeting was sponsored by the Chinese Journal of Pathology.
Amoy Diagnostics is the only company in China to have obtained SFDA approval (for clinical use in China) and CE certification (for IVD use in Europe) for EGFR, KRAS and BRAF mutation testing.
